Evelyn Barnett

Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

T. Miller, T. Kipps, J. Gabrilove, 2016, Haematologica.

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

T. Miller, T. Kipps, J. Gabrilove, 2013 .

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

S. Lonial, S. Trudel, P. Richardson, 2020 .

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Michael L. Wang, I. Lossos, C. Reeder, 2017, Journal of Hematology & Oncology.

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael L. Wang, I. Lossos, C. Reeder, 2016 .